Abstract
The past few months have seen encouraging successes for neutralizing antibodies against HIV; human monoclonal antibodies targeting conserved HIV envelope epitopes potently neutralized primary virus isolates, including strains of different clades. In primates, passive immunization with combinations containing human monoclonal antibodies completely prevented infection, even after mucosal virus challenges. Epitopes recognized by the protective monoclonal antibodies are important determinants for protection and provide a rational basis for AIDS vaccine development.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
AIDS Vaccines
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antibody Specificity
-
Clinical Trials, Phase I as Topic
-
HIV / immunology
-
HIV Antibodies / adverse effects
-
HIV Antibodies / immunology
-
HIV Antibodies / therapeutic use*
-
HIV Infections / immunology
-
HIV Infections / prevention & control
-
HIV Infections / therapy*
-
Humans
-
Immunization, Passive
-
Neutralization Tests
-
Primates
-
T-Lymphocytes, Cytotoxic / immunology
Substances
-
AIDS Vaccines
-
Antibodies, Monoclonal
-
HIV Antibodies